1,092 results

#112005-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 24, 2019

Academic Institutions and Nonprofits only

#176750-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

July 21, 2023

Academic Institutions and Nonprofits only

#128485-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-iSeroSnFR-Nlgn (#128485). In addition to the viral particles, you will also receive purified pAAV-CAG-iSeroSnFR-Nlgn plasmid DNA. CAG-driven expression of a fluorescent reporter for serotonin (localized to dendrites). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Unger et al Cell. 2020 Dec 12. pii: S0092-8674(20)31

Feb. 27, 2024

Academic Institutions and Nonprofits only

#20071-AAV1

Ready-to-use AAV1 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#50972-AAV8

Ready-to-use AAV8 particles produced from AAV-SYP1-miniSOG-T2A-mCherry (#50972). In addition to the viral particles, you will also receive purified AAV-SYP1-miniSOG-T2A-mCherry plasmid DNA. Syn-driven, InSynC expression. These AAV preparations are suitable purity for injection into animals.

Roger Tsien

Lin et al Neuron. 2013 Jul 24;79(2):241-53. doi: 1

Sept. 22, 2025

Academic Institutions and Nonprofits only

#176755-AAV1

Ready-to-use AAV1 particles produced from AAV-mDlx-jGCaMP8s-WPRE (#176755). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8s-WPRE plasmid DNA. mDlx-driven expression of the calcium sensor jGCaMP8s in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Sept. 12, 2023

Academic Institutions and Nonprofits only

#176750-AAV9

Ready-to-use AAV9 particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Nov. 13, 2025

Academic Institutions and Nonprofits only

#50472-AAV5

Ready-to-use AAV5 particles produced from pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine (#50472). In addition to the viral particles, you will also receive purified pAAV-GFAP-HA-rM3D(Gs)-IRES-mCitrine plasmid DNA. GFAP-driven HA-tagged rM3D(Gs) and bicistronic mCitrine expression, for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#198516-AAV1

Ready-to-use AAV1 particles produced from pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE (#198516). In addition to the viral particles, you will also receive purified pAAV_EF1a-DIO-PdCO-mScarlet-ER-miniWPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of the optimized opsin PdCO in frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#221463-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only